Call on the Trump administration and HHS Deputy Secretary nominee Chris Klomp to disclose agreements and related materials between the federal government and pharmaceutical companies concerning most-favored-nation pricing, the GENEROUS Model, and anything of value provided to manufacturers.

Ron Wyden · Oregon · Democratic

oversight impact 2.70 specificity 0.86 extraction confidence 85%

Commitment kind: action. Promised action: Call on the Trump administration and HHS Deputy Secretary nominee Chris Klomp to disclose agreements and related documents concerning pharmaceutical pricing deals.. Promised outcome: Disclosure of government-pharmaceutical manufacturer agreements and materials so Congress and the public can assess whether patients and taxpayers receive savings.. Deadline: unknown; not assumed expired. As Senate Finance Committee Ranking Member, Wyden renewed an oversight demand ahead of a committee vote on Chris Klomp's nomination to be Deputy Secretary of HHS.

Occurrences

In the letter, sent to Chris Klomp, the nominee to be Deputy Secretary at HHS, and the lead negotiator of these agreements, Wyden calls on the administration to disclose: All agreements between HHS and pharmaceutical manufacturers concerning most-favored-nation pricing. All agreements and other materials related to the GENEROUS Model, including agreements with pharmaceutical manufacturers and states Medicaid programs. All documents concerning anything of value provided to pharmaceutical manufacturers in connection with these agreements.

Wyden called on the Trump administration and HHS Deputy Secretary nominee Chris Klomp to disclose federal pharmaceutical pricing agreements and related materials before the Finance Committee votes on Klomp's nomination.

[2026-09-24] Wyden Renews Demand for Trump's Deals with Big Pharma | The United States Senate Committee on Finance
primary · press_release · model gpt-5.5

Evidence

verified · Source version 75291 · locator 2503

All agreements between HHS and pharmaceutical manufacturers concerning most-favored-nation pricing.

Fetched verbatim passage. AI summary (separate from source): Wyden's official Senate Finance release documents that he called on the Trump administration, through HHS Deputy Secretary nominee Chris Klomp, to disclose MFN drug-pricing agreements.

delivered same_term A for effort

[2026-09-24] Wyden Renews Demand for Trump's Deals with Big Pharma | The United States Senate Committee on Finance
primary · model gpt-5.5 · confidence 97%

verified · Source version 75291 · locator 2603

All agreements and other materials related to the GENEROUS Model

Fetched verbatim passage. AI summary (separate from source): The same official release states that Wyden's demand included GENEROUS Model materials, matching the claim's specific disclosure target.

delivered same_term A for effort

[2026-09-24] Wyden Renews Demand for Trump's Deals with Big Pharma | The United States Senate Committee on Finance
primary · model gpt-5.5 · confidence 96%

unverified · Source version 75294 · locator unknown

all documents concerning anything of value provided to manufacturers in connection with these agreements

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Wyden's signed letter to Chris Klomp specifically requested records about items of value provided to pharmaceutical manufacturers in connection with the agreements.

delivered same_term A for effort

09.23.2026 Letter to Chris Klomp on MFN Deal Documents
secondary · model gpt-5.5 · confidence 97%

unverified · Source version 75294 · locator unknown

I expect your response by September 30.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The letter set a concrete September 30, 2026 response deadline, showing the disclosure demand remained pending at the as-of date absent a documented response.

delivered same_term A for effort

09.23.2026 Letter to Chris Klomp on MFN Deal Documents
secondary · model gpt-5.5 · confidence 93%

verified · Source version 75296 · locator 1883

Until these details are made public, I will do everything in my power to impede Mr. Klomp’s nomination

Fetched verbatim passage. AI summary (separate from source): Wyden publicly tied his opposition to Klomp's nomination to the administration's failure to disclose the requested drug-deal details.

delivered same_term A for effort

[2026-09-24] Wyden Opposes Trump HHS and Tax Nominees | The United States Senate Committee on Finance
secondary · model gpt-5.5 · confidence 92%

verified · Source version 75298 · locator 65

To require the Department of Health and Human Services to release documents

Fetched verbatim passage. AI summary (separate from source): Before the September lookback demand, Wyden introduced legislation aimed at compelling HHS disclosure of the same category of confidential drug-pricing deal documents.

delivered same_term A for effort

S. 4355 (Introduced-in-Senate)
secondary · model gpt-5.5 · confidence 90%

Assessments

Public state: delivered As of 2026-09-30 · verified · . Original AI recommendation (not independently established): delivered. same_term A for effort

The verified commitment was an action commitment: Wyden would call on the Trump administration and HHS Deputy Secretary nominee Chris Klomp to disclose drug-pricing agreements and related materials. Verified passages show Wyden made that disclosure demand for MFN agreements and GENEROUS Model materials, and further tied Klomp's nomination to making the details public. This proves the promised call/demand occurred; there is no need to prove the administration actually disclosed the documents because that would be a separate outcome promise.

provider codex_cli · model gpt-5.5 · confidence 93%